The Korea Leukemia Patients Organization (KLPO) expressed its regrets to the government and Novartis Korea for excluding the first CAR-T treatment Kymriah from the agenda for deliberation at the Review Committee for Cancer Diseases meeting that was held on the 14th.

On the 19th, KLPO said, “A disconcerting situation occurred. Kymriah was not even able to enter the first gateway for NHI listing and be put on the agenda for deliberation for the Review Committee for Cancer Diseases meeting. We will fight with the government and Novartis for the reimbursement of Kymriah.”

The patient group demanded an explanation from the company and authorities on why Kymriah was not put up as an agenda